TIVDAK
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cervical Cancer
Conditions
Cervical Cancer
Trial Timeline
May 7, 2025 → Dec 13, 2028
NCT ID
NCT06952660About TIVDAK
TIVDAK is a approved stage product being developed by Pfizer for Cervical Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06952660. Target conditions include Cervical Cancer.
What happened to similar drugs?
7 of 20 similar drugs in Cervical Cancer were approved
Approved (7) Terminated (0) Active (13)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06952660 | Approved | Recruiting |
Competing Products
20 competing products in Cervical Cancer